Join the Schizophrenia group to help and get support from people like you.
Schizophrenia News (Page 5)
Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia
Intra-Cellular Therapies Announces U.S. FDA Approval of Caplyta (lumateperone) for the Treatment of Bipolar Depression in Adults
Caplyta is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or...
FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder
DUBLIN, June 1, 2021 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment...
FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults
NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) – Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS)...
FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia
Miami, FL And Jersey City, NJ, October 15, 2019 -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Administration ...
FDA Approves Perseris (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
SLOUGH, England and RICHMOND, Va., July 27, 2018 /PRNewswire/ – Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved Perseris, the first...
FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the...
Allergan Receives FDA Approval for Vraylar (cariprazine) in the Maintenance Treatment of Schizophrenia
DUBLIN, Nov. 13, 2017 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Vraylar...
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
FDA Medwatch Alert: Paliperidone Extended-Release Tablets 3mg by Teva Pharmaceuticals: Recall - Dissolution Test Failure
ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A,...
FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil)...
Sunovion’s Latuda (lurasidone) Receives FDA Approval to Treat Adolescents with Schizophrenia
MARLBOROUGH, Mass.--(BUSINESS WIRE)--January 28, 2017 Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug...
U.S. FDA Approves Labeling Update of Rexulti (brexpiprazole) for Maintenance Treatment of Schizophrenia
Princeton, New Jersey and Valby, Denmark – September 23, 2016 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food a...
FDA Medwatch Alert: Olanzapine: Drug Safety Communication - FDA Warns About Rare But Serious Skin Reactions
ISSUE: FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. FDA is adding a new warning to the...
FDA Medwatch Alert: Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems
ISSUE: FDA is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
Seroquel, Abilify, Latuda, quetiapine, Vraylar, olanzapine, risperidone, Zyprexa, aripiprazole, view more... Risperdal, Rexulti, Seroquel XR, Geodon, Invega, Invega Sustenna